DexCom, Inc. (NASDAQ:DXCM) EVP Sells $274,241.90 in Stock

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares of the company's stock, valued at $5,839,974.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

DexCom Stock Down 1.9 %

DXCM stock traded down $2.66 during mid-day trading on Wednesday, hitting $133.86. The stock had a trading volume of 3,222,232 shares, compared to its average volume of 2,995,804. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a fifty day moving average of $129.06 and a 200 day moving average of $116.16. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $51.61 billion, a price-to-earnings ratio of 104.21, a PEG ratio of 2.31 and a beta of 1.20.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm's revenue was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.34 earnings per share. On average, equities analysts expect that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Institutional Investors Weigh In On DexCom

Several institutional investors and hedge funds have recently modified their holdings of the business. KB Financial Partners LLC acquired a new stake in shares of DexCom in the first quarter worth about $72,000. Bartlett & CO. Wealth Management LLC acquired a new stake in DexCom in the 4th quarter worth approximately $27,000. DSM Capital Partners LLC acquired a new stake in DexCom in the 4th quarter worth approximately $28,000. Riverview Trust Co bought a new stake in DexCom during the first quarter worth approximately $32,000. Finally, Valley National Advisers Inc. grew its holdings in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent analyst reports. Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a research report on Wednesday, April 3rd. Piper Sandler upped their price objective on shares of DexCom from $135.00 to $150.00 and gave the company an "overweight" rating in a research note on Tuesday, December 19th. Raymond James lifted their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, January 23rd. UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a report on Wednesday, April 10th. Finally, StockNews.com upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research report on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, DexCom has an average rating of "Moderate Buy" and an average target price of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.